Carrie Bourdow
Chief Executive Officer presso TREVENA, INC.
Patrimonio netto: 43 442 $ in data 31/03/2024
Posizioni attive di Carrie Bourdow
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| TREVENA, INC. | Chief Executive Officer | 01/10/2018 | - |
| Chairman | 01/01/2024 | - | |
| President | 01/10/2018 | - | |
| Director/Board Member | 01/10/2018 | 01/01/2024 | |
| Chief Operating Officer | 02/02/2018 | 01/10/2018 | |
| Corporate Officer/Principal | 04/05/2015 | 02/02/2018 |
Storia della carriera di Carrie Bourdow
Precedenti posizioni note di Carrie Bourdow
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| NABRIVA THERAPEUTICS PLC | Director/Board Member | 23/06/2017 | 30/07/2023 |
| Independent Dir/Board Member | 23/06/2017 | 30/07/2023 | |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 20/02/2020 | 07/03/2023 |
| Independent Dir/Board Member | 20/02/2020 | 07/03/2023 | |
| CUBIST PHARMACEUTICALS INC | Sales & Marketing | 01/05/2013 | 01/05/2015 |
Formazione di Carrie Bourdow
| Hendrix College | Undergraduate Degree |
| Southern Illinois University | Masters Business Admin |
Statistiche
Distribuzione geografica
| Stati Uniti | 6 |
| Irlanda | 2 |
Posizioni
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| Chief Executive Officer | 1 |
Settori
| Health Technology | 5 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| TREVENA, INC. | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| Aziende private | 2 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Carrie Bourdow
- Esperienza
